Search results for "Multivariate Analysis"

showing 10 items of 1076 documents

Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers.

2005

Abstract Purpose: Glucose transporter-1 (GLUT-1), a target gene of hypoxia-inducible factor-1, has been considered a candidate endogenous marker of tumor hypoxia. Expression of GLUT-1 may also serve as an indicator for the induction of the transcriptional response to hypoxia, which has been linked to enhanced proliferation, resistance to therapy, and metastatic propagation of cancer cells. Overexpression of GLUT-1 has been shown to correlate with poor prognosis in several tumor entities, among them cancers of the uterine cervix. The validity of these hypotheses is investigated. Experimental Design: The expression of GLUT-1 was assessed in 80 biopsies of Eppendorf oxygenation measurement tra…

OncologyCancer Researchmedicine.medical_specialtyPathologyMonosaccharide Transport ProteinsUterine Cervical NeoplasmsBiologyInternal medicinemedicineHumansSurvival analysisNeoplasm StagingProportional Hazards ModelsCervical cancerGlucose Transporter Type 1Tumor hypoxiaProportional hazards modelGlucose transporterHypoxia (medical)Middle Agedmedicine.diseaseImmunohistochemistrySurvival AnalysisOxygenOncologyCancer cellMultivariate AnalysisImmunohistochemistryFemalemedicine.symptomClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

ErbB-3 predicts survival in ovarian cancer.

2006

Background HER3 (erbB-3) is a member of the epidermal growth factor receptor (EGFR) family. After dimerization with other members of the EGFR family several signal transduction cascades can be activated, including phosphoinosite 3′-kinase (PI3-K)/Akt and extracellular signal-regulated kinase (ERK1/2). Here, we studied a possible association between HER3 expression and prognosis in patients with ovarian cancer. Methods Tumor tissue of 116 consecutive patients diagnosed with primary epithelial ovarian cancer between 1986 and 1995 was analyzed immunohistochemically for HER3 expression. A possible influence of HER3 expression on survival was studied by multivariate Cox regression adjusting for …

OncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-3Receptor ErbB-2ErbBPredictive Value of TestsInternal medicinemedicineBiomarkers TumorOdds RatioHumansEpidermal growth factor receptorStage (cooking)Protein kinase BNeoplasm StagingProportional Hazards ModelsGynecologyOvarian NeoplasmsbiologyProportional hazards modelbusiness.industryHazard ratioCarcinomaMiddle Agedmedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisUp-RegulationGene Expression Regulation NeoplasticOncologyMultivariate Analysisbiology.proteinFemaleSignal transductionOvarian cancerbusinessJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

2021

Abstract Purpose: The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcriptomic ITH of colon cancer and understanding its potential prognostic implications. Experimental Design: We deconvoluted the transcriptomic profiles of 1,779 tumors from the PETACC8 trial and 155 colon cancer cell lines as weighted sums of the four CMSs, using the Weighted In Silico Pathology (WISP) algorithm. We assigned to each tumor and cell line a combination of up to three …

OncologyMaleCancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancer[SDV]Life Sciences [q-bio]CellContext (language use)[SDV.CAN]Life Sciences [q-bio]/CancerBiologyTranscriptome[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineCell Line TumormedicineTumor MicroenvironmentHumansTreatment resistancehealth care economics and organizationsAgedbusiness.industryGene Expression ProfilingHazard ratiomedicine.diseasePrognosisSurvival Rate[SDV] Life Sciences [q-bio]medicine.anatomical_structureOncologyColonic NeoplasmsFemalePersonalized medicinebusiness
researchProduct

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, m…

2016

BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease.METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to De…

OncologyMaleDenmarkProgrammed Cell Death 1 ReceptorCohort Studies0302 clinical medicineRecurrenceAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineTreatment FailureReed-Sternberg CellsHazard ratioHematologyHodgkin DiseaseVinblastineDacarbazineSTAT1 Transcription FactorItalylymphoma PET Hodgkin030220 oncology & carcinogenesisDisease ProgressionbiomarkerFemalemedicine.drugAdultmedicine.medical_specialtyDacarbazineAntigens Differentiation MyelomonocyticSettore MED/08 - Anatomia PatologicaVinblastineDisease-Free Survival03 medical and health sciencesBleomycinAntigens CDInternal medicineHumansRetrospective StudiesFluorodeoxyglucosebusiness.industryRetrospective cohort studyPET scanmedicine.diseaseLymphomaSurgeryABVDReed–Sternberg cellDoxorubicinPositron-Emission TomographyMultivariate Analysisclassical Hodgkin's lymphoma:PolandbusinessBiomarkers030215 immunology
researchProduct

A Tetra-Panel of Serum Circulating miRNAs for the Diagnosis of the Four Most Prevalent Tumor Types

2020

The purpose of this study is to clinically validate a series of circulating miRNAs that distinguish between the 4 most prevalent tumor types (lung cancer (LC)

OncologyMaleLung NeoplasmsColorectal cancerlcsh:ChemistryProstate cancer0302 clinical medicinelcsh:QH301-705.5SpectroscopyEarly Detection of CancerAged 80 and over0303 health sciencesArea under the curveGeneral MedicineMiddle AgedEarly diagnosisprostate cancer3. Good healthComputer Science Applications030220 oncology & carcinogenesisArea Under CurveFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyBreast Neoplasmscolorectal cancerCatalysisArticleInorganic Chemistry03 medical and health sciencesBreast cancerbreast cancerInternal medicinemedicineHumansCirculating MicroRNAPhysical and Theoretical ChemistryLung cancerMolecular Biology030304 developmental biologyAgedNeoplasm StagingReceiver operating characteristicbusiness.industryOrganic ChemistryCancerProstatic Neoplasmsmedicine.diseaseCirculating MicroRNAlung cancerlcsh:Biology (General)lcsh:QD1-999ROC CurveCase-Control StudiesMultivariate Analysiscirculating microRNAsbusinessInternational Journal of Molecular Sciences
researchProduct

Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STE…

2011

Introduction: Treatment of elderly patients with small cell lung cancer (SCLC) is based on scanty evidence. Methods: Patients with extensive SCLC, age >70 years, and performance status 0-2 were eligible for a study looking for optimal two-drug combination of gemcitabine (Gem) with vinorelbine (Vin), etoposide (Eto), cisplatin (Cis), or carboplatin (Car). Gemcitabine dose was the same (1000 mg/m2, days 1-8) in all combinations. A two-stage minimax flexible design for response was applied to GemVin combination (Vin 25 mg/m2, days 1-8). For GemCar, GemCis, GemEto, a phase I-II Bayesian design was applied, looking for the optimal dose of the partner drugs. Objective response rate ≥60% and un…

OncologyMaleLung NeoplasmsDeoxycytidineCarboplatinchemistry.chemical_compoundElderlyAntineoplastic Combined Chemotherapy Protocols80 and overCarcinoma Small CellMultivariate AnalysiEtoposideEtoposidePlatinum compoundsAged 80 and overArea under the curveSCLCVinorelbinePrognosisElderly; Etoposide; Gemcitabine; Platinum compounds; SCLC; Vinorelbine; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma Small Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome; Vinblastine; VinorelbineTreatment OutcomeOncologyPlatinum compoundToxicityFemalemedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPrognosiVinorelbineVinblastineDisease-Free SurvivalInternal medicinemedicineHumansAgedProportional Hazards ModelsCisplatinAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industryCarcinomaSmall CellGemcitabineGemcitabineCarboplatinSurgeryLung NeoplasmchemistryMultivariate AnalysisProportional Hazards ModelQuality of LifeCisplatinbusiness
researchProduct

P-cadherin expression and survival rate in oral squamous cell carcinoma: an immunohistochemical study

2005

Abstract Background P-cadherin (P-cad) is a transmembrane molecule involved in the cell-cell adhesion and similar to E-cadherin (E-cad), but less investigated in oncology, especially in in vivo studies. Aims of the present study were to assess the prevalence of P-cad expression in oral squamous cell carcinoma (OSCC) and to verify whether P-cad can be considered a marker of prognosis in patients with OSCC. Methods In a retrospective study, a cohort of 67 OSCC patients was investigated for P-cad expression and its cellular localization by immunohistochemistry; some respective healthy margins of resection were similarly investigated as standard controls. After grouping for P-cad expression, OS…

OncologyMalePathologyCancer ResearchCytoplasmTime FactorsCohort StudiesSurgical oncologyCellular localizationMouth neoplasmAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCadherinsPrognosisImmunohistochemistryTreatment OutcomeOncologycell-cell adhesionCarcinoma Squamous CellImmunohistochemistryRegression AnalysisFemaleMouth NeoplasmsResearch ArticleAdultmedicine.medical_specialtyAdolescentlcsh:RC254-282Internal medicinemedicineGeneticsBiomarkers TumorHumanscardiovascular diseasesGrading (tumors)Survival rateAgedProportional Hazards ModelsRetrospective StudiesModels StatisticalProportional hazards modelCadherinbusiness.industryCell MembraneCateninstomatognathic diseasesMultivariate AnalysisCadherinbusinessCell Adhesion Molecules
researchProduct

Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fet…

2015

The lifetime utility of liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) is still controversial. The aim of this study was to ascertain when LT is cost-effective for HCC patients, with a view to proposing new transplant selection criteria. The study involved a real cohort of potentially transplantable Italian HCC patients (n = 2419 selected from the Italian Liver Cancer group database) who received nontransplant therapies. A non-LT survival analysis was conducted, the direct costs of therapies were calculated, and a Markov model was used to compute the cost utility of LT over non-LT therapies in Italian and US cost scenarios. Post-LT survival was calculated using t…

OncologyMaleTime FactorsDatabases Factualmedicine.medical_treatmentCost-Benefit AnalysisLiver transplantationClinical endpointLiver NeoplasmsSurgery; Transplantation; HepatologyHealth Care Costshepatocellular carcinomaMiddle AgedMarkov ChainsTumor BurdenModels EconomicTreatment OutcomeItalyHepatocellular carcinomaFemaleQuality-Adjusted Life Yearsalpha-FetoproteinsAlpha-fetoproteinMonte Carlo Methodmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIADecision Support Techniquesalpha-fetoproteinPredictive Value of TestsInternal medicinemedicineHumansneoplasmsSurvival analysisAgedProportional Hazards ModelsRetrospective StudiesTransplantationHepatologyProportional hazards modelbusiness.industryPatient SelectionRetrospective cohort studymedicine.diseaseSurvival Analysisdigestive system diseasesUnited StatesSurgeryLiver TransplantationTransplantationMultivariate AnalysisSurgerybusiness
researchProduct

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

2012

Summary Lenalidomide is an effective drug in low-risk myelodysplastic syndromes (MDS) with isolated del(5q), although not all patients respond. Studies have suggested a role for TP53 mutations and karyotype complexity in disease progression and outcome. In order to assess the impact of complex karyotypes on treatment response and disease progression in 52 lenalidomide-treated patients with del(5q) MDS, conventional G-banding cytogenetics (CC), single nucleotide polymorphism array (SNP-A), and genomic sequencing methods were used. SNP-A analysis (with control sample, lymphocytes CD3+, in 30 cases) revealed 5q losses in all cases. Other recurrent abnormalities were infrequent and were not ass…

OncologyMalemedicine.medical_specialtyMultivariate analysisCD3Single Nucleotide Polymorphism ArrayBiologyPolymorphism Single NucleotideInternal medicinemedicineHumansImmunologic FactorsPlateletLenalidomideIn Situ Hybridization FluorescenceLenalidomideAgedAged 80 and overMyelodysplastic syndromesCytogeneticsKaryotypeHematologyMiddle Agedmedicine.diseaseChromosome BandingThalidomideTreatment OutcomeMyelodysplastic SyndromesImmunologyMutationbiology.proteinDisease ProgressionChromosomes Human Pair 5FemaleChromosome Deletionmedicine.drugBritish journal of haematology
researchProduct

Metabolic disorders across hepatocellular carcinoma in Italy

2018

Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, pati…

OncologyMaleobesityDatabases FactualHepatocellular carcinoma0302 clinical medicineRisk FactorsProspective cohort studydiabetesMetabolic disorderLiver NeoplasmsDiabeteshepatocellular carcinomaMiddle AgedMetabolic syndromePortal vein thrombosisItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIADiabetes; Hepatocellular carcinoma; Metabolic syndrome; Obesitymetabolic syndrome03 medical and health sciencesDatabasesMetabolic DiseasesInternal medicinemedicineDiabetes MellitusHumansObesityFactualAgedNeoplasm StagingRetrospective StudiesHepatologybusiness.industryCarcinomaHepatocellularHepatologymedicine.diseaseSurvival AnalysisBCLC Stagediabetes; hepatocellular carcinoma; metabolic syndrome; obesity; Aged; Carcinoma Hepatocellular; Databases Factual; Diabetes Mellitus; Female; Humans; Italy; Liver Neoplasms; Male; Metabolic Diseases; Middle Aged; Multivariate Analysis; Neoplasm Staging; Obesity; Retrospective Studies; Risk Factors; Survival AnalysisdiabeteMultivariate AnalysisLiver functionMetabolic syndromebusiness
researchProduct